INCYTE CORP

Listed Company

INCYCIK 0000879169NasdaqLarge AcceleratedServices-Commercial Physical & Biological ResearchDelawareFY ends Dec 31

Period

FY 2025

Revenue

$5.14B

Net Income

$1.29B

Total Assets

$6.96B

Equity

$5.17B

Shares Out

199.78M

Op. Cash Flow

$1.41B

Business

INCYTE CORP is a global biopharmaceutical company that discovers, develops and commercializes proprietary small molecule and biologic therapeutics. Its main products include approved medicines such as JAKAFI (ruxolitinib), OPZELURA (ruxolitinib cream), PEMAZYRE (pemigatinib), MONJUVI/MINJUVI (tafasitamab), ICLUSIG (ponatinib), ZYNYZ (retifanlimab) and NIKTIMVO (axatilimab), alongside numerous clinical-stage programs. The company organizes its efforts principally into Hematology/Oncology and Inflammation and Autoimmunity (IAI), including a Dermatology franchise, and maintains collaborations and licensing relationships. It commercializes and distributes products in the United States, Europe, Japan and other markets via specialty and retail pharmacies, wholesalers, distributors and partnered channels.

Summary from filing dated 2025-02-10

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenues	5,141	4,241	3,696	3,395	2,986
Cost of product revenues (including definite-lived intangible amortization)	372	312	255	207	151
Contract dispute settlement	−242	0	0	—	—
Research and development	2,050	2,607	1,628	1,586	1,458
Selling, general and administrative	1,376	1,242	1,156	1,002	740
Asset impairment	76	0	6	—	—
(Gain) loss on change in fair value of acquisition-related contingent consideration	−6	20	29	12	15
(Profit) and loss sharing under collaboration agreements	0	−1	2	8	37
Total costs, expenses and other	3,626	4,180	3,075	2,815	2,400
Income from operations	1,515	61	621	579	586
Interest income	106	129	158	40	—
Interest expense	−2	−2	−3	−3	—
Gain on equity investments	21	116	44	−88	—
Other, net	25	13	14	−519,000	11
Income before provision for income taxes	1,664	317	834	529	570
Provision for income taxes	378	284	237	188	−378
Net income	1,287	33	598	341	949
Basic (in dollars per share)	6.59	0.16	2.67	1.53	4.3
Diluted (in dollars per share)	6.41	0.15	2.65	1.52	4.27
Basic (in shares)	195	207	224	222	220
Diluted (in shares)	201	211	226	224	222

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	3,098	1,688	3,213	2,951	2,057
Marketable securitiesavailable-for-sale (amortized cost $480,793 and $469,917 as of December 31, 2025 and 2024, respectively; allowance for credit losses $0 as of December 31, 2025 and 2024)	483	470	443	—	—
Accounts receivable	1,024	853	744	645	616
Inventory	101	59	63	42	28
Prepaid expenses and other current assets	318	169	183	167	126
Total current assets	5,024	3,239	4,645	4,093	3,119
Restricted cash	2	2	2	2	2
Long term equity investments	48	19	188	—	—
Inventory	342	348	207	79	29
Property and equipment, net	731	763	752	739	724
Finance lease right-of-use assets, net	28	31	26	26	28
Other intangible assets, net	117	114	124	129	151
Goodwill	133	156	156	156	156
Deferred income tax asset	515	762	632	458	468
Other assets	18	11	52	25	37
Total assets	6,958	5,444	6,782	5,841	4,933
Accounts payable	210	197	110	278	172
Accrued compensation	228	189	153	139	109
Accrued and other current liabilities	1,032	1,212	936	701	534
Finance lease liabilities	5	4	3	3	3
Acquisition-related contingent consideration	41	39	38	37	37
Total current liabilities	1,515	1,642	1,240	1,157	854
Acquisition-related contingent consideration	80	154	174	184	207
Finance lease liabilities	30	34	29	30	32
Other liabilities	165	168	149	99	70
Total liabilities	1,790	1,997	1,592	1,471	1,163
Commitments and contingencies (Note 17)	—	—	—	—	—
Preferred stock, $0.001 par value; 5,000,000 shares authorized; none issued or outstanding as of December 31, 2025 and 2024	0	0	0	0	0
Common stock, $0.001 par value; 400,000,000 shares authorized; 198,460,009 and 193,434,305 shares issued and outstanding as of December 31, 2025 and 2024, respectively	198,000	193,000	224,000	223,000	221,000
Additional paid-in capital	4,928	4,533	5,016	4,792	4,567
Accumulated other comprehensive income (loss)	25	−13	13	15	−19
Retained earnings (accumulated deficit)	214	−1,073	160	−437	−778
Total stockholders equity	5,167	3,448	5,190	4,370	3,770
Total liabilities and stockholders equity	6,958	5,444	6,782	5,841	4,933

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net income	1,287	33	598	341	949
Depreciation and amortization	93	89	83	68	58
Stock-based compensation	249	266	216	188	183
Deferred income taxes	248	−86	−159	57	−466
Other, net	15	−9	17	17	1
Accounts receivable	−171	−112	−99	−29	−134
Prepaid expenses and other assets	−156	10	−42	−31	−64
Inventory	−59	−128	−170	−68	−21
Accounts payable	7	88	−168	105	73
Accrued and other liabilities	−148	279	231	220	131
Net cash provided by operating activities	1,413	335	496	970	749
Purchase of long term investments	−8	0	−10	0	−34
Sale of equity investments	8,000	285	45,000	0	10
Capital expenditures	−59	−86	−32	−78	−181
Payments for intangible assets	−25	−14	−15	0	0
Purchases of marketable securities	−296	−258	−456	−80	−235
Maturities of marketable securities	285	231	306	79	232
Net cash (used in) provided by investing activities	−103	158	−208	−79	−208
Repurchase of Common Stock	0	−2,005	0	0	—
Excise tax paid on repurchase of Common Stock	−19	0	0	—	—
Proceeds from issuance of Common Stock under stock plans	222	49	36	61	59
Tax withholdings related to restricted and performance share vesting	−77	−40	−29	−26	−30
Payment of finance lease liabilities	−5	−4	−3	−3	−2
Payment of contingent consideration	−20	−22	−24	—	—
Net cash provided by (used in) financing activities	101	−2,022	−20	−794,000	6
Effect of exchange rates on cash, cash equivalents, and restricted cash	−2	3	−7	3	−4
Net increase (decrease) in cash, cash equivalents, and restricted cash	1,410	−1,526	262	894	544
Cash paid for contract dispute settlement	295	0	0	—	—
Unpaid purchases of property and equipment	5	3	5	3	27
Unpaid excise tax on repurchase of common stock	0	19	0	0	—
Leased assets obtained in exchange for new operating lease liabilities	3	10	5	7	14
Leased assets obtained in exchange for new finance lease liabilities	937,000	9	2	2	2

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro